Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway.

Front Immunol · 2025 · PMC12328149 · PMID 40777014

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

slightly non-significantp= 0.18not close (p > 0.1)

For all groups, a slightly non-significant upregulation was seen during relapse (MOGAD: 4940.14 ± 6155.12 vs 6803.20 ± 8977.60, p= 0.18, Supplementary Figure S1a ; NMOSD: 88.86 ± 185.50 vs 348.30 ± 779.80, p=0.29, Supplementary Figure S1b ; MS: 3427.21 ± 5236.38 vs 5547.27 ± 6779.68, p=0.53, Supplementary Figure S1c ).

also in 39 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.